Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Colorectal Cancer Centre, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Cancer Res Treat. 2018 Jan;50(1):283-292. doi: 10.4143/crt.2016.537. Epub 2017 May 8.
The purpose of this study was to investigate the prognostic implications of carcinoembryonic antigen (CEA) levels that are inconsistent with Response Evaluation Criteria in Solid Tumor (RECIST) responses in metastatic colorectal cancer patients.
We retrospectively evaluated 360 patients with at least one measurable lesion who received first-line palliative chemotherapy. CEA-response was defined as CEA-complete response (CR; CEA normalization), CEA-partial response (PR; ≥ 50% decrease in CEA levels), CEA-progressive disease (PD; ≥ 50% increase in CEA levels), and CEA-stable disease (SD; non-CR/PR/PD). Overall survival (OS) and progression-free survival (PFS) were evaluated according to CEA-response.
In RECIST-PR patients, poorer CEA-response was associated with disease progression at the subsequent evaluation. In RECIST-SD patients, CEA-CR and -PR were associated with lower disease progression rates than CEA-PD at the subsequent evaluation. Correlations between survival outcome and CEA-response in same-category RECIST patients were assessed. In RECIST-PR patients, discordant CEA-response (CEA-PD/SD) was associated with poorer survival than CEA-CR/PR (median OS and PFS, 44.0 and 15.4 [CEA-CR], 28.9 and 12.5 [CEA-PR], 21.0 and 9.8 [CEA-SD], and 13.0 and 7.0 [CEA-PD] months, respectively; all p < 0.001). In RECIST-SD patients, favorable CEA-response produced better survival (median OS and PFS, 26.8 and 21.0 [CEA-CR], 21.0 and 11.0 [CEA-PR], 16.1 and 8.2 [CEA-SD], and 12.2 and 6.0 [CEA-PD] months, respectively; all p < 0.001). RECIST-PD patients with CEA-CR showed longer OS than those with CEA-PD. Multivariate analysis demonstrated that discordant CEA-response is a powerful prognostic factor for RECIST-PR and RECIST-SD patients.
Among patients of the same RECIST-response categories, CEA-response patterns are significantly prognostic and strongly predictive of subsequent evaluation outcomes.
本研究旨在探讨与实体瘤反应评估标准(RECIST)应答不一致的癌胚抗原(CEA)水平对转移性结直肠癌患者预后的影响。
我们回顾性评估了 360 名至少有一个可测量病变的患者,这些患者接受了一线姑息化疗。CEA 反应定义为 CEA 完全缓解(CR;CEA 正常化)、CEA 部分缓解(PR;CEA 水平下降≥50%)、CEA 进展(PD;CEA 水平升高≥50%)和 CEA 稳定(SD;非 CR/PR/PD)。根据 CEA 反应评估总生存期(OS)和无进展生存期(PFS)。
在 RECIST-PR 患者中,较差的 CEA 反应与后续评估时的疾病进展相关。在 RECIST-SD 患者中,与 CEA-PD 相比,CEA-CR 和 -PR 与后续评估时较低的疾病进展率相关。评估了同类别 RECIST 患者的生存结果与 CEA 反应之间的相关性。在 RECIST-PR 患者中,不一致的 CEA 反应(CEA-PD/SD)与较差的生存相关,与 CEA-CR/PR 相比(中位 OS 和 PFS,44.0 和 15.4 [CEA-CR]、28.9 和 12.5 [CEA-PR]、21.0 和 9.8 [CEA-SD]、13.0 和 7.0 [CEA-PD] 个月,均 p<0.001)。在 RECIST-SD 患者中,有利的 CEA 反应产生更好的生存(中位 OS 和 PFS,26.8 和 21.0 [CEA-CR]、21.0 和 11.0 [CEA-PR]、16.1 和 8.2 [CEA-SD]、12.2 和 6.0 [CEA-PD] 个月,均 p<0.001)。RECIST-PD 患者中 CEA-CR 的 OS 长于 CEA-PD 患者。多变量分析表明,不一致的 CEA 反应是 RECIST-PR 和 RECIST-SD 患者强有力的预后因素。
在同一 RECIST 反应类别患者中,CEA 反应模式具有显著的预后意义,并强烈预测后续评估结果。